Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

214 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Ketamine hydrochloride may lessen neuropathic pain in patients with cancer. It is not yet known whether ketamine hydrochloride given together with the best pain management is more effective than a placebo given together with the best pain management in treating neuropathic pain in patients with cancer.

PURPOSE: This randomized phase III trial is studying ketamine hydrochloride given together with the best pain management to see how well it works compared with giving a placebo together with the best pain management in treating cancer patients with neuropathic pain.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ketamine and Neuropathic Pain

NCT02467517

Neuropathic Pain

UNKNOWN PHASE2

Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients

NCT00471445

Neurotoxicity Pain Peripheral Neuropathy +1 more

COMPLETED PHASE3

MC5-A Scrambler Therapy in Reducing Peripheral Neuropathy Caused by Chemotherapy

NCT01290224

Pain Peripheral Neuropathy

COMPLETED PHASE2

Neotrofin for Treatment of Chemotherapy-Induced Peripheral Neuropathy

NCT00041795

Peripheral Nervous System Diseases Chemotherapy-Induced Peripheral Neuropathy

COMPLETED PHASE2

Neuropathic Pain in Patients With Cancer

NCT00474916

Neuropathic Pain

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

Primary

* To determine whether ketamine hydrochloride given in addition to best standard pain management improves malignant neuropathic pain compared to best standard pain management alone in patients with cancer.

Secondary

* To compare initial treatment benefit (at day 4 of assessment period of 16 days) using the sensory component of the McGill Short-Form Questionnaire.
* To compare difference in overall pain between the study arms based on the pain-intensity visual-analogue score (VAS).
* To compare difference in neuropathic pain between the study arms based on the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) pain scale.
* To assess worst pain score (index neuropathic site) between the two arms.
* To compare patient distress between the two arms based on NCCN Distress Thermometer.
* To assess the side effects and tolerability of trial drug.
* To assess the effect of intervention on quality of life scores (based on Euroqol thermometer), anxiety and depression (based on HADS), and opioid requirements.

OUTLINE: This is a multicenter study.

* Stage 1 (Run-in Period): Opioid doses are optimized, under a defined schedule, for up to a maximum of 10 days to ensure that all patients are on an optimized and stable regimen\* prior to randomization. Following the run-in-period, patients undergo reassessment. Patients who have improved pain scores (i.e., \< 4/10 on the visual-analogue score in the past 24 hours or \< 5 McGill Sensory Scale Score) are taken off the study. Patients whose scores have not improved continue on to Stage 2 of the study.

NOTE: \*Stable regimen is defined as the same dose of controlled release and no more variation than 2 breakthrough opioid doses over the normal for that patient for a period of 48 hours.

* Stage 2 (Titration Period): Patients are randomized to 1 of 2 treatment arms.

* Arm I: Patients receive oral ketamine hydrochloride 4 times a day. Doses are titrated until when analgesia is achieved or individual side effects appear, for up to 14 days.
* Arm II: Patients receive an oral placebo 4 times a day. Doses are titrated until when analgesia is achieved or individual side effects appear, for up to 14 days.
* Stage 3 (Assessment Period): Patients receive the trial medication (i.e., ketamine hydrochloride or placebo) at the fixed optimum dose (reached during the titration period) for 16 days.

Patients are allowed to receive breakthrough opioids at any time during the study.

Patients complete quality-of-life and pain-assessment questionnaires periodically. Some patients may undergo blood sample collection periodically for pharmacogenomics studies at a later date.

Peer Reviewed and Funded or Endorsed by Cancer Research UK.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ketamine hydrochloride

Intervention Type DRUG

pharmacogenomic studies

Intervention Type OTHER

questionnaire administration

Intervention Type OTHER

assessment of therapy complications

Intervention Type PROCEDURE

quality-of-life assessment

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

DISEASE CHARACTERISTICS:

* Histologically confirmed cancer
* Index neuropathic pain ≥ 4 on 0-10 (as defined by Leeds Assessment of Neuropathic Symptoms and Signs) that is related to underlying malignancy or resulting from treatment received for this malignancy
* McGill Sensory Scale Score \> 5
* Received a trial of an adjuvant analgesic (gabapentin or amitriptyline or both)

PATIENT CHARACTERISTICS:

* Life expectancy ≥ 2 months
* Fertile patients must use effective contraception
* Able to comply with study procedures
* Diastolic blood pressure ≤ 100 mm Hg at screening
* No seizures in past 2 years
* Not actively hallucinating
* No cerebrovascular disease (strokes)
* No psychotic disorders or cognitive impairment

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* At least 6 weeks since prior and no concurrent chemotherapy or radiotherapy that is likely to affect neuropathic pain
* No change in tumoricidal treatment during the period of the study that is likely to alter pain during the course of the study
* No concurrent class I antiarrhythmic drugs

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No